The Covance-Lilly deal of 2008 was a huge milestone cleared in the evolution of big-pharma and the drug development cycle. In 2008 it had became obvious to everyone involved in the industry that certain synergies could be made between CROs and the larger pharmaceutical companies of the world, and thus the 1.6 billion dollar covance-lilly deal was born. Now, more than one and a half years later the relationship between the two organizations is still growing. According to an article from the CenterWatch website dated March 15,2010, the two have decided that Lilly will award Covance a three year biotechnology services contract, that includes the addition of a new 15 million dollar facility, hiring the 20 Lilly employees from the current division, and adding several others over the next few years.
This news is only proof that the relationships that CROs and Pharma have are still in their infancy. Continued development of the existing and yet to be discovered opportunities will only lead to faster development, testing, and approval for drugs and devices of all types. Better products which are delivered down the pipeline faster will only prove more profitable for all involved. More profits for the companies and better products for consumers is a "win-win" for everyone.
No comments:
Post a Comment